Clearside Biomedical, Inc. (CLSD)

Market Cap	66.16M
Revenue (ttm)	7.70M
Net Income (ttm)	-31.88M
Shares Out	75.84M
EPS (ttm)	-0.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	942,545
Open	0.920
Previous Close	0.930
Day's Range	0.801 - 0.930
52-Week Range	0.801 - 2.120
Beta	2.20
Analysts	Strong Buy
Price Target	5.33 (+511.03%)
Earnings Date	Nov 12, 2024

About CLSD

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 2, 2016
• Employees: 30
• Stock Exchange: NASDAQ
• Ticker Symbol: CLSD
• Website: https://clearsidebio.com

Financial Performance

In 2023, Clearside Biomedical's revenue was $8.23 million, an increase of 519.89% compared to the previous year's $1.33 million. Losses were -$32.49 million, -1.40% less than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for CLSD stock is "Strong Buy." The 12-month stock price forecast is $5.33, which is an increase of 511.03% from the latest price.

Price Target

$5.33

(511.03% upside)

Analyst Consensus: Strong Buy